

Rapid Communication

A Pilot Study of Correlations between an Ifn-Gamma Elispot Assay and the Tuberculin Skin Test

Antas PRZ*, Silva D and Ponte CGG

Laboratório de Imunologia Clínica, Instituto Oswaldo Cruz-Fiocruz, Brazil

*Corresponding author: Antas PRZ, Laboratório de Imunologia Clínica, Instituto Oswaldo Cruz-Fiocruz, Av. Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brazil

Received: October 09, 2017; Accepted: October 23, 2017; Published: November 09, 2017

Abstract

The global resurgence of Tuberculosis (TB), supported by HIV pandemic and *Mycobacterium tuberculosis* multi-drug resistance strains, underscores needs for new diagnostic measures. Here, persons with suspected TB infection were enrolled to compare the *in vitro* specific T cell-immune responses, using in-house IFN γ ELISPOT assay and Tuberculin Skin Test (TST). The TST is subject to variations, since PPD contains mixture several antigens also present in other mycobacteria. To avoid this drawback, *M. tuberculosis* proteins hsp65, Ag85A and Ag85B were used in PBMC cultures. No significant correlation was identified between the tests to detect potential associations, but the TST tended to show better sensitivity (83.3%) to detect confirmed TB infection. However, the Ag85A tended for higher specificity (83.4%). Only one individual showed nil results. Conversely, 2 suspected TB patients showed high reactivity to both Ag85, plus a strength TST (> 16 mm). Not surprisingly, there was a very significant agreement when the 2 Ag85 isoforms were compared. Larger studies are warranted to confirm those findings.

Keywords: Tuberculosis; ELISPOT; Antigen 85

Introduction


Tuberculosis (TB) is a major cause of illness and death worldwide. The rising of global incidence of TB is blamed for that burden mainly in developing countries [1]. The importance of cell-mediated immunity in the protective response against *Mycobacterium tuberculosis* is well established. At diagnosis, Tuberculin Skin Test (TST) is subject to substantial variations and other limitations, and false-positive results are common. Lately, peripheral blood-derived IFN γ responses to *M. tuberculosis*-RD1 specific antigens have been investigated for the management of TB. The results suggest that those assays may have advantages over the TST, in terms of higher specificity, better correlation with exposure to *M. tuberculosis*, and less cross-reactivity due to TB vaccination and other mycobacterial infections [2]. However, no other *M. tuberculosis* specific antigen has been tested in those platforms so far.

Essential requirements for the immune response in TB are the antigens recognized by the effective either CD4 or CD8 T lymphocytes. For several years, important efforts have been concentrated to identify candidate molecules for inclusion in a novel vaccine/booster against and immunodiagnostic for TB [3]. Evaluations of the T cell function in response to recombinant, soluble antigens have been performed in an endemic TB area. In previous studies, our data have shown that the IFN γ response within the TB patient group was enhanced in comparison to that of the controls, and that the CD69 and CD25 *in vitro* expression on T cells in response to Antigen 85B (Ag85B) and Ferritin was highest after 24 and 72 h, respectively [4,5].

In this study, we have extended those characterizations of specific *in vitro* cellular immune responses in terms of IFN γ production by Enzyme Linked Immunospot (ELISPOT) assay, comparing those data with Tuberculin Skin Test (TST) performed during a shelter

screening [6]. Accordingly, selected comparisons among TST and *M. tuberculosis* recombinant proteins hsp65, Ag85A and Ag85B were made in primary Peripheral Blood Mononuclear Cell (PBMC) cultures purified within 24 hours of obtaining the specimens of 15 suspected TB patients. Demographic data, eligibility and exclusion criteria for those individuals are described elsewhere [7]. TST in duration was performed after intradermal placement of 5 tuberculin units of PPD (Statens Serum Institute, Copenhagen, Denmark). The IFN- γ ELISPOT was assayed as recommended by the T.SPOT-TB[®] manufacturer (Oxford Immunotech Inc. Oxford, UK) and slightly modified replacing the original panels A and B, by adding 5.0 μ g/ml of either *M. tuberculosis* hsp65 or Ag85A or Ag85B (Kindly provided by Drs. T. Ottenhoff, LUMC, The Netherlands, and E. Sampaio, FIOCRUZ, Brazil). After developed and by using an AID plate reader (Germany), a reactive sample was scored if > 6 spots were formed. For a statistical analysis, the software Instat 3 was used to estimate the coefficient of correlation.

At screening, the frequencies of IFN- γ ELISPOT responses at the single-cell level already subtracted from the background and expressed as number of Spot Forming Colony (SFC) for the 3 *M. tuberculosis* recombinant antigens tested in the suspected TB patients are showed in the Figure 1. As internal controls, positive responses to PHA, and negative ones to empty plasmidial vector, were detected in all individuals (data not shown). A total of 8 out of 15 individuals assayed responded to TST, defined as the standard > 10 mm in duration cut off. On the other hand, only one individual (# 5297) did not show any SFC to all *M. tuberculosis* antigens used, neither to TST. However, 2 suspected TB patients (# 5267 and # 5375) showed a high reactivity (> 29 SFC) to both Ag85, plus a positive and strength TST (20 mm and 16 mm, respectively). Overall, the 53% of TST reactivity was more frequent than for the IFN- γ ELISPOT: 27% for



Ag85A, 20% for Ag85B and 13% for hsp65. It should be emphasized that 6 individuals were confirmed as TB infected ones, as detected by RD1 antigens performed in parallel (data not shown). When we used this certified immunodiagnostic tool (T.SPOT-TB[®]) to sort out the positive group, the results are the following: 83.3% of TST reactivity compared to 66.7% for Ag85A, 50.0% for Ag85B and 16.7% for hsp65 by IFN- γ ELISPOT. However, the specificity changed the ranking as 83.4% of the IFN- γ ELISPOT employing the Ag85A was higher than 75.0% for both TST and Ag85B, but lower than for hsp65 (52.8%) IFN- γ ELISPOT. Based on that, and also to compare the magnitude of IFN- γ ELISPOT responses with the TST in duration size, correlation studies were preliminary performed. It's worth of note that due to limited number of individuals no correlation was found when the 2 methods were compared, regardless the antigens employed or criterion. Not surprisingly, there was a very significant agreement ($p < 0.004$) in the mean number of SFC when the 2 Ag85 isoforms were compared.

New strategies for specific TB diagnosis and prevention of *M. tuberculosis* transmission are mandatory. The most obvious limitation of the current study was the small sample size. Even though, the results of this pilot study show that our in-house and modified IFN- γ ELISPOT assay, which uses a different set of *M. tuberculosis* antigens from the original and commercial kit, seems to be less accurate and sensitive in identifying subjects suspected to be infected with TB than the TST. On the other hand, the IFN- γ ELISPOT employing the Ag85A tended for a better specificity in detect confirmed TB infection when compared to the TST. Furthermore, on the basis of IFN- γ ELISPOT responses, we have not been able to define suitable *M. tuberculosis* antigens that correlate with TST other than the 2 in *M. tuberculosis* RD1. Arend and colleagues [8] confirmed that two commercial IFN- γ release assays employing specific RD1 antigens correlated with exposure parameters to TB, whereas the TST did not. A possible lack of sensitivity of these assays with a 10mm or larger TST cut off warrants further investigation.

The members of the Ag85 family are found in all mycobacteria, and sequence comparison indicates that the Ag85 gene family arose by duplication of an ancestral gene, before the emergence of the actually known mycobacterial species [9]. Based on that, we

were not surprised that the only significant agreement was found between Ag85A and Ag85B, regardless the study size. Indeed, the three members of this mycolil-transferases family have shown higher immune reactivity [10].

Possible explanations for the low sensitivity of the *in vitro* assays rely on the concentration of the antigen employed, although a dose-response curve was previously generated and then corroborated latter [4,5]. The definition of positive or negative responses to ELISPOT assays is still empirical, even if a general consent on how to consider positive results exists in the literature [11]. Thus, we decided for maintain the cut off value as suggested by the T.SPOT-TB[®] manufacturer. Would this hamper the final result? Earlier, an ELISPOT cut-off for RD1 proteins was set at 4-8 SFC, with little benefit from the final results, and another for PPD skin test at 9-13mm was more rational when comparing with that ELISPOT data [12]. In contrast, Diel et al. [13] used a 10mm in duration cut-off for the TST among occasional contacts, and showed strong agreement between TST and ELISPOT in non BCG-vaccinated persons.

In conclusion, we primarily rule out the possibility to have the *M. tuberculosis* hsp65 recombinant protein included in an IFN- γ ELISPOT assay in order to screen for suspected TB individuals. In contrast, the potential of this *in vitro* assay employing the Ag85A deserves more attention. Further investigation among a larger population is warranted.

Acknowledgement

The authors are indebted to Dr. Timothy Sterling and also very grateful to Dr. Ian Durrant and Oxford Immunotech personnel, Dr. Richard D'Aquila and staffs at Vanderbilt University Medical Center for assistance with laboratory facilities, and nursing staff of TB ward (Alisa Haushalter and Fernanda Maruri) for helping with patients' recruitment. This study was partly financed by Oxford Immunotech Inc. (UK), CAPES and IOC-Fiocruz (Brazil). CGGP and DS are the recipients of CAPES and FAPERJ scholarships, respectively; and PRZA is granted with CNPq and FAPERJ research fellowships (PQ-2 and JCNE, respectively).

References

1. World Health Organization (WHO) report. Global tuberculosis report. 2014.

2. Zimmerli L, Nüesch R, Elzi L. Update on tuberculosis: interferon-gamma assays. *Schweiz Rundsch Med Prax.* 2007; 96: 2051-2057.
3. Brodin P, Rosenkrands I, Andersen P, Cole ST, Brosch R. ESAT-6 proteins: protective antigens and virulence factors? *Trends Microbiol.* 2004; 12: 500-508.
4. Cardoso FLL, Antas PRZ, Milagres AS, Geluk A, Franken LMC, Oliveira EB, et al. T cell responses to the Mycobacterium tuberculosis specific antigen ESAT-6 in Brazilian tuberculosis patients. *Infect Immun.* 2002; 70: 6707-6714.
5. Antas PRZ, Oliveira EB, Milagres AS, Franken LMC, Ottenhoff THM, Klatser P, et al. Kinetics of T cell-activation molecules in response to Mycobacterium tuberculosis antigens. *Mem Inst Oswaldo Cruz.* 2002; 97: 1097-1099.
6. Pepper T, Joseph P, Mwenya C, McKee GS, Haushalter A, Carter A, et al. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. *Int J Tuberc Lung Dis.* 2008; 12: 397-403.
7. Antas PR, Ding L, Hackman J, Reeves-Hammock L, Shintani AK, Schiffer J, et al. Decreased CD4+ lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis. *J Allergy Clin Immunol.* 2006; 117: 916-923.
8. Arend SM, Thijsen SF, Leyten EM, Bouwman JJ, Franken WP, Koster BF, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. *Am J Respir Crit Care Med.* 2007; 175: 618-627.
9. Content J, de la Cuvellerie A, De Wit L, Vincent-Levy-Frébault V, Ooms J, De Bruyn J. The genes coding for the antigen 85 complexes of Mycobacterium tuberculosis and Mycobacterium bovis BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of M. tuberculosis. *Infect Immun.* 1991; 59: 3205-3212.
10. Mustafa AS. Development of new vaccines and diagnostic reagents against tuberculosis. *Mol Immunol.* 2002; 39: 113-119.
11. Codecasa L, Mantegani P, Galli L, Lazzarin A, Scarpellini P, Fortis C. An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection. *J Clin Microbiol.* 2006; 44: 1944-1950.
12. Jeffries DJ, Hill PC, Fox A, Lugos M, Jackson-Sillah DJ, Adegbola RA, et al. Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia. *Int J Tuberc Lung Dis.* 2006; 10: 192-198.
13. Diel R, Ernst M, Döscher G, Visuri-Karhe L, Greinert U, Niemann S, et al. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test. *Eur Respir J.* 2006; 28: 16-23.